Leucocyte Interferon-alpha for Patients with Chronic Hepatitis C Intolerant to Other alpha-Interferons
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Alpha-interferon (α-IFN) is the treatment of choice for chronic hepatitis C but most patients experience adverse effects which sometimes lead to the suspension of therapy. Recently, higher doses of α-IFN or prolonged therapy have increased the number of cases of intolerance.
In this open study we evaluated the efficacy and safety of leucocyte interferon-alpha (IFNα) [6MU three times a week] in 43 patients with chronic hepatitis C who had been intolerant to previous treatment courses with recombinant or lymphoblastoid IFNα. All patients were treated for 6 months and followed-up for an additional 6 months.
End of treatment responders were patients in whom hepatitis C virus (HCV)-RNA had been eradicated from the blood by the end of treatment, sustained responders were those patients who maintained negative HCV-RNA at the end of follow-up, and the remaining patients were considered non-responders. Adverse effects were monitored by interviews, laboratory and clinical examinations.
Five patients (11.6%) discontinued the treatment, four due to the reappearance of previous adverse effects, and one due to an ex novo adverse effect. In six patients the dose had to be halved. At the end of treatment 11 patients (25.6%) had negative serum HCV-RNA. After discontinuation of therapy, disease flared in four patients, thus seven patients were sustained responders.
This study shows that leucocyte IFNα at a dose of 6MU three times a week is well tolerated in patients previously intolerant to recombinant or lymphoblastoid IFNα, allowing a high percentage of them to complete a course of treatment in terms of duration and dose.
- Hoofnagle JH, Di Bisceglie AM. Treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347–56 CrossRef
- Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778–89 CrossRef
- McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485–92 CrossRef
- Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon-alfa 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493–9 CrossRef
- Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352: 1426–32 CrossRef
- Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon-alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–72 CrossRef
- Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–65 CrossRef
- Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11241 patients with chronic viral hepatitis treated with alpha interferon. J Hepatol 1996; 24: 38–47 CrossRef
- Okanoue T, Sakamoto S, Itoh Y, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996; 25: 283–91 CrossRef
- Montalto G, Soresi M, Carroccio A, et al. Comparative responses to three different types of interferon-alpha in patients with chronic hepatitis C. Curr Med Res Opin 1998; 14: 235–41 CrossRef
- Cacopardo B, Benanti F, Brancati G, et al. Leukocyte interferon-alpha retreatment for chronic hepatitis C patients previously intolerant to other interferons. J Viral Hepat 1998; 5: 333–9 CrossRef
- Gaeta GB, Di Virgilio D, Russo G, et al. Human leukocyte interferon-alpha in chronic hepatitis C resistant to recombinant or lymphoblastoid interferon-alpha: a randomised controlled trial. J Viral Hepat 1997; 4: 209–14 CrossRef
- Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading, staging. Hepatology 1994; 19: 1513–20 CrossRef
- Giannini C, Thiers V, Nousbaum JB, et al. Comparative analysis of two assays for genotyping hepatitis C virus based on genotype-specific primers of probes. J Hepatol 1995; 23: 146–53
- Colombatto P, Oliveri F, Leandro G, et al. Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis. Ital J Gastroenterol Hepatol 1997; 29: 441–7
- Toccaceli F, Rosati S, Scuderi M, et al. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepatogastroenterology 1998; 45: 1748–52
- Malaguarnera M, Di Fazio I, Restuccia S, et al. Interferon alpha-induced depression in chronic hepatitis C patients: comparison between different types of interferon alpha. Neuropsychobiology 1998; 37: 93–7 CrossRef
- Cagnoni C, Pancotti D, Carrara G. Management of patients with HCV infection poorly tolerant to recombinant Interferon alpha. Hepatogastroenterology 2000; 47: 199–203
- Gattoni A, Romano C, Cecere A, et al. Efficacy of human leukocyte interferon treatment in elderly patients with hepatitis C virus-related chronic liver disease. Arch Gerontol Geriatr 1996; 22-23Suppl. 5: 305–12
- Dughera L, Battaglia E, Serra AM, et al. Human leukocyte interferon-alpha treatment for chronic HCV-related hepatitis in hemophilic patients previously intolerant to other interferons-alpha. Dig Dis Sci 2002; 47: 427–31 CrossRef
- Custro N, Montalto G, Scafidi V, et al. Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy. J Endocrinol Invest 1997; 20: 374–80
- Custro N, Carroccio A, Ganci A, et al. Glycemie homeostasis in chronic viral hepatitis and liver cirrhosis. Diabetes Metab 2001; 27: 476–81
- Leucocyte Interferon-alpha for Patients with Chronic Hepatitis C Intolerant to Other alpha-Interferons
Volume 17, Issue 3 , pp 201-205
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Dipartimento di Medicina Clinica e delle Patologie Emergenti, Servizio di Prevenzione e Cura delle Malattie Epato-biliari e Cattedra di Medicina Interna, Università di Palermo, Via del Vespro 141, Palermo, 90127, Italy